$CWNM .128 Crown Marketing Takes Aim at Diabetes

[b]$CWNM [/b].128 Crown Marketing Takes Aim at Diabetes Medication

CHAPEL HILL, NC, [b][color=blue]Jan 31, 2013[/color][/b] (MARKETWIRE via COMTEX) -- Crown Marketing (OTCQB: CWNM) is pleased to announce that it has achieved positive in-vitro testing results of the most widely prescribed Diabetes drug commonly known as Metformin. As the accompanying image indicates, Crown's Controlled Drug Delivery Device (CDDT) is less than half the size of the 500mg dosage tablet, and may reduce and ameliorate many of the gastrointestinal side effects of Metformin. The most common adverse effects of Metformin are gastrointestinal upset including diarrhea, cramps, nausea and vomiting. Crown believes it can significantly reduce or eliminate these effects with its patented technology.

Patients also have issues about the taste and odor associated with the medication. Common complaints are that it "smells fishy" and can leave a metallic taste in the mouth. This is critical because it impacts patient compliance -- if it tastes or smells bad, patients oftentimes will not take the medication as directed. Crown's CDDT can overcome these issues due to its novel, diffusion based design and its impermable coating. According to IMS figures, the total market sales for all forms of Metformin were $1.6 billion, with sales of Metformin extended-release formulation alone accounting for over $460 million last year.

About The Company:

Crown's Controlled Drug Delivery Technology (CDDT) is a novel controlled-release technology, harnessing the principles of diffusion through precise mathematical formulas.

The spectrum and reliability of pharmacokinetic profiles achievable with this technology is superior to currently marketed formulations. Its simple design allows for a high level of flexibility in matching chronotherapeutic requirements. Cost-efficiencies in the commercial manufacturing process, when compared to other drug delivery technologies, may constitute its most important competitive advantage.

The objective of intelligent drug delivery design amounts to maximizing the percent of the time drug plasma levels are within the therapeutic range and avoiding patient exposure to potentially toxic (High) or sub-therapeutic (Low) levels.

Crown's cost-effective application of controlled delivery technologies will play a major role in the expansion of the pharmaceutical, OTC and nutraceuticals industry through our ability to improve on the performance of immediate release products in a manner tangible to manufacturers and consumers.

More information can be found at: www.crowncddt.com